FindTrial
Sign In

Expanded Access to Rovalpituzumab Tesirine

Expanded Access to Rovalpituzumab Tesirine

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT03503890
Enrollment
Unknown
Registered
2018-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2019-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

Keywords

Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme

Brief summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Rovalpituzumab Tesirine prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Interventions

DRUGrovalpituzumab tesirine

intravenous

Sponsors

AbbVie
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* The participant must not be eligible for a Rovalpituzumab Tesirine clinical trial. * Pediatric participants may be evaluated on a case by case basis.

Exclusion criteria

* None.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026